Mizuho analyst Ann Hynes maintains Universal Health Services (NYSE:UHS) with a Buy and lowers the price target from $153 to $121.
Yet Again: Johnson & Johnson Subsidiary Seeks Stay On Thousands Of Cancer Lawsuits Associated With Talc Products
Johnson & Johnson's (NYSE: JNJ) subsidiary, LTL Management, has reportedly requested a U.S. judge to delay 38,000 lawsuits again. These lawsuits accuse their baby powder and other talc products of causing cancer.